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Abstract
Genetic polymorphisms in oxidative stress pathway genes may contribute to carcinogenesis, disease recurrence, treatment
response, and clinical outcomes. We applied a pathway-based approach to determine the effects of multiple single
nucleotide polymorphisms (SNPs) within this pathway on clinical outcomes in non-muscle-invasive bladder cancer (NMIBC)
patients treated with Bacillus Calmette-Gue ´rin (BCG). We genotyped 276 SNPs in 38 genes and evaluated their associations
with clinical outcomes in 421 NMIBC patients. Twenty-eight SNPs were associated with recurrence in the BCG-treated group
(P,0.05). Six SNPs, including five in NEIL2 gene from the overall and BCG group remained significantly associated with
recurrence after multiple comparison adjustments (q,0.1). Cumulative unfavorable genotype analysis showed that the risk
of recurrence increased with increasing number of unfavorable genotypes. In the analysis of risk factors associated with
progression to disease, rs3890995 in UNG, remained significant after adjustment for multiple comparison (q,0.1). These
results support the hypothesis that genetic variations in host oxidative stress genes in NMIBC patients may affect response
to therapy with BCG.
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Introduction
In the United States, bladder cancer is the fourth most common
cancer and the eighth leading cause of death from cancer in men,
with an estimated 69,250 new cases and 14,990 deaths in 2011
[1]. Most (75%–85%) bladder cancers are non–muscle invasive at
first diagnosis, which include superficial non-invasive (pTa),
minimally-invasive (pT1), or carcinoma in situ (CIS) [2]. Overall
bladder cancer recurrence rates of non–muscle invasive bladder
cancer (NMIBC) have been reported to be 31–78% at 5 years, and
for high risk groups, 17–45% patients will progress to muscle
invasive disease at 5 years [3–4]. Transurethral resection (TUR) is
the gold standard for diagnosis and low risk Ta T1 transitional cell
carcinoma (TCC) treatment [5]. However, recurrence at 3 months
for patient with multifocal tumors varied between 7% and 46%,
suggesting different TUR qualities [5].
Tumor cells often show an increased level of DNA oxidation
products and oxidation-induced mutations [6]. Oxidative stress
causes protein, lipid, and DNA damage and is a critical
pathophysiological event implicated in several human pathologies,
including cancer [7–8]. However, accelerated repair of oxidized
DNA can protect cancer cells from harmful oxidative DNA
damage [9] and is associated with metastasis and poor patient
survival [10]. Many oxidative stress genes, such as eNOS, MnSOD,
and GPX are polymorphic and have been studied for association
with cancer risks and clinical outcomes [11–14].
To reduce the recurrence and progression of NMIBC,
intravesical installation of Bacillus Calmette-Gue ´rin (BCG) is
often administered after TUR. BCG administration has been
reported to induce local oxidative stress, which may mediate the
antitumor activity [15]. We hypothesized that polymorphisms of
oxidative stress–pathway genes may modulate the risk of re-
currence and progression in BCG treated patients. To test this
hypothesis, we conducted a study to evaluate the effects of 276
single-nucleotide polymorphisms (SNPs) in 38 key genes from the
oxidative-stress pathway. To our knowledge, this is the first study
to explore the association between a comprehensive panel of
polymorphisms of the oxidative stress–pathway genes and risk of
recurrence or progression in NMIBC patients, particularly in those
receiving BCG therapy.
Materials and Methods
Ethics Statement
Written informed consents were obtained from all patients prior
to enrollment in this study. The study was approved by the
Institutional Review Boards at MD Anderson Cancer Center and
Baylor College of Medicine.
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The study population and enrollment procedures were de-
scribed previously [16]. Patients were recruited from The
University of Texas MD Anderson Cancer Center and Baylor
College of Medicine as a part of an ongoing project since 1999. All
patients were identified by reviewing daily electronic clinic
schedules at the Urology and GU Medical Oncology clinics.
The NMIBC patients were newly diagnosed, histologically
confirmed, and had not been previously treated with chemother-
apy or radiotherapy at the time of recruitment. There were no
restrictions for age, gender, ethnicity, histology or stage on
recruitment. Since more than 90% of our recruited cases were
transitional cell carcinoma (TCC), we only included TCC cases in
this study. In addition, the majority of patients in our study
population (90.6%) were Caucasians; therefore, we restricted the
analysis to Caucasians to limit the confounding effect from
population stratification. A total of 421 NMIBC patients were
included in this study.
Epidemiological and Clinical Data Collection
M.D. Anderson staff interviewers administered a 45-minute in-
person interview to all participants to collect data on demographic
characteristics, tobacco use history, medical history, occupation
and exposure, and family history of cancer. At the end of the
interview, all participants donated a small blood sample for DNA
extraction before receiving any treatment. Patients treated with
TUR were followed up with periodic cystoscopic examinations,
and subsequently some were treated with BCG. This treatment
consisted of either BCG for 6 weekly instillations (induction BCG,
iBCG) or iBCG + maintenance BCG (mBCG) in 3 weekly cycles
given at 3, 6, 12, 18, 24, and 30 months after iBCG [17]. Clinical
data were obtained from medical records by trained chart review
specialists. The end points of outcome assessment in this study
included recurrence and progression, which was calculated from
the date of diagnosis to the date of endpoint events, death or last
followup, whichever came first. Tumor recurrence was defined as
a newly detected bladder tumor following a negative follow-up
cystoscopy, and tumor progression was defined as the transition
from non–muscle-invasive to invasive or metastatic disease.
Patients who died or lost to follow up before the endpoint events
were censored.
Selection and Genotyping of Polymorphisms in Oxidative
Stress–Pathway Genes
We compiled gene list using SNPs3D bioinformatic tools
(http://www.snps3d.org) [18]. We then identified tagging SNPs
from the Hapmap database (http://www.hapmap.com). Similar to
our previous study [19], all SNPs fit the following criteria: r
2,0.8,
minor allele frequency (MAF) .0.05, and located within 10 kb
upstream of the 59-untranslated region (UTR) and 10 kb
downstream of the 39-UTR of the gene. We also included
potentially functional SNPs with MAFs .0.01 (e.g., coding SNPs
and SNPs in UTRs, promoters, or splice sites).The genotyping was
performed using Illumina’s iSelect custom SNP array (Illumina,
San Diego, CA) and the average call rate was 99.7%.
Luciferase Reporter Assay to Determine Effect of the
NEIL2:rs4639 Alleles on Regulation of NEIL2 Expression
by microRNAs
A reporter construct derived from pGL3 (Ambion) containing
the 39-UTR of NEIL2 was generated as follows: a 1.35-kb
fragment of the NEIL2 39-UTR was amplified from genomic DNA
with the following primers: Forward1, 59-GAAGATGGGTTA-
CAGAGGCT; Reverse1, 59-CAGACATCGTGGTGACAGAG.
Subsequently, a 0.35-kb nested PCR fragment of 39-UTR
containing rs4639 was generated with primers: Forward2, 59-
AATTCTAGAGGGATACAGGCACCAAGAGGCGG; Re-
verse2, 59- GTAGGCCGGCCGCGAGTAACAGTGAGCTT-
TAT. The amplified product was digested with XbaI and FseI
and subcloned into pGL3 control vector. Variant NEIL2 allele
construct was generated by site-directed mutagenesis with primers:
Forward3, 59- GATTTGTTGgACAATTCAGGAATCAAGG
and Reverse3, 59-TCCTGAATTGTcCAACAAATCAACAGT-
CAC.
Table 1. Oxidative stress gene SNPs and disease recurrence in BCG-treated
&, Texas NMIBC patients enrolled in an ongoing
molecular epidemiologic study of bladder cancer, 1999-present.
Recurrence in BCG subgroup
No. Times in
bootstrap
sample
P,0.05
Best Model
# Yes/No
SNP* Gene Genotype ww wv vv HR (95%CI)
{ P
rs804256
{ NEIL2 T/C RES 41/36 51/42 18/4 4.58(2.61–8.02) 1610
27 91
rs804276
{ NEIL2 A/G RES 33/31 47/41 30/10 2.71(1.75–4.20) 9610
26 99
rs4639
{ NEIL2 A/G RES 28/28 52/44 30/10 2.60(1.68–4.03) 2610
25 98
rs2173962 SOD1 A/G DOM 93/81 16/1 1/0 2.45(1.42–4.23) 1610
23 58
rs804267
{ NEIL2 T/C DOM 61/32 39/37 10/13 0.53(0.36–0.78) 1610
23 92
rs8191604 NEIL2 A/C DOM 73/40 31/39 6/3 0.54(0.36–0.81) 3610
23 76
*SNPs that remained significant after controlling for multiple comparisons by q-value with FDR (false discovery rate) less than 10%. All NEIL2 SNPs in this table were in
different haplotype blocks with r
2,0.8.
{Adjusted by age, sex, smoking status, tumor stage, and tumor grade.
#Best model: the model with smallest P value; DOM: dominant model, RES: recessive model.
ww, homozygous wild-type genotype; wv, heterozygous variant genotype; vv, homozygous variant genotype.
{SNPs with P value ,0.05 in least 80% of the bootstrap samples.
&Patients treated with iBCG or iBCG plus mBCG.
doi:10.1371/journal.pone.0038533.t001
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38533Figure 1. Kaplan-Meier estimates of recurrence-free or progression-free survival in NMIBC patients. (A) Kaplan-Meier estimates of
recurrence-free survival in all NMIBC patients grouped by the three risk groups as categorized by the number of unfavorable genotypes in the
oxidative stress pathway. Recurrence-free median survival time [MST] =42.3, 12.5, and 5.6 months for low, medium, and high risk patients,
respectively (P log-rank=0.0001). (B) Kaplan-Meier estimates of recurrence-free survival in BCG-treated patients grouped by the three risk groups as
categorized by the number of unfavorable genotypes in the oxidative stress pathway. MST =66.1, 25.4, and 16.6 months) for low, medium, and high
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by Dr. Barton Grossman’s lab and were authenticated within six
months prior to our study [20]. UM-UC-9 cells were transfected
with 0.5 mg of the wild-type or variant NEIL2 39-UTR construct
along with 5 pmol of negative RNA control (scrambled sequence),
miR-421, or miR-1200 microRNA (miRNA) mimic (Sigma-
Aldrich, St. Louis, MO) and 10 ng of pGL4 Renilla luciferase
reporter (Ambion, Carlsbad, CA) using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) for 36 hours. The reporter expression
was analyzed using the Dual-Luciferase Reporter Assay System
(Promega, Madison, WI) and luciferase activities were measured in
a FLUOstar Optima microplate reader (BMG Labtech, Cary,
NC). Each assay was repeated independently three times with five
replicates.
Statistical Analyses
Statistical analyses were performed using STATA 10.0 (Stata
Corp., College Station, TX, USA). The x
2 test (for categorical
variables) or Student’s t-test (for continuous variables) was used to
compare characteristics between the groups of patients with or
without disease outcome. Linkage disequilibrium (LD) between
individual SNPs was evaluated, with r
2.0.8 were defined as being
in the same haplotype block.
For each patient, we calculated the recurrence-free survival time
as the time from diagnosis to recurrence, progression or to the date
of death or last follow-up. Patients who were lost to follow-up or
died before the end-point event were censored. We calculated
person-years at risk within each genotype category as the sum of
the recurrence-free survival times of all subjects in that genotype
category. The effects of genotypes of SNPs on bladder cancer
outcomes were estimated as hazard ratios and 95% confidence
intervals (95% CI) using multivariate Cox regression under the
dominant, recessive, and additive models of inheritance adjusted
for age, gender, and smoking status, where appropriate. To
control for multiple comparison, a q value (a false discovery rate
[FDR]-adjusted P value) was used to adjust the significance level
for individual SNPs. The q value was calculated by the q value
package implemented in the R software. A bootstrap resampling
method, using 100 bootstrap samples, was applied to internally
validate the results. P for trend value was calculated with the
number of unfavorable genotypes as continuous variable using
unconditional Cox regression.
All analyses were stratified by age, gender, smoking status,
tumor stage, tumor grade, and treatment. For the cumulative
effects of multiple genetic variants, the adverse genotypes were
summed and categorized by the number of adverse genotypes in
subjects. To evaluate the cumulative effects of genetic variants, we
summed up adverse genotypes (genotypes associated with signif-
icantly increased risk in the main effect analysis after adjustment
for multiple comparisons) for each subject. Kaplan-Meier plots
and log-rank tests were applied to compare the differences
between the recurrence-free survival times of different genotypes.
Non-parametric Wilcoxon Ranksum test was used to compare
differences in luciferase activities in the reporter assay. All
statistical tests were two-sided.
Results
Characteristics of the Study Population
Of the 421 Caucasian patients we followed, 346 (82.2%) were
men and 75 (17.8%) were women. Among them, 232 (55.1%) had
disease recurrence, with a median recurrence-free survival time of
14.05 months. As shown in Table S1, no significant differences
for recurrence rate were identified based on age (P=0.68), sex
(P=0.11), smoking status (P=0.69), cancer stage (P=0.13), or
cancer grade (P=0.19). There were no significant differences in
progression by age (P=0.05) or smoking status (P=0.96). Men
had higher rates of disease progression than women (P=0.01) and
patients with a higher stage or grade were also more likely to
experience progression (P,0.01). Since BCG was primarily
administered to those with higher risk of recurrence [21], we
compared different BCG treatments on risks of recurrence and
progression. Compared to iBCG, mBCG treatment was signifi-
risk patients, respectively (P log-rank=0.0001). (C) Overall Kaplan-Meier estimates of the effect of UNG:rs3890995 genotypes on progression-free
survival in NMIBC patients (in the three risk subgroups, progression-free survival were greater than the follow-up time of 132.6 months). Compared
with patients carrying homozygous variant genotype, those with at least one wildtype allele showed longer progression-free survival time (P log-
rank=0.04). ww-homozygous wildtype; wv- heterozygous; vv-homozygous variant.
doi:10.1371/journal.pone.0038533.g001
Table 2. Cumulative effect of unfavorable genotypes in oxidative stress pathway on total and BCG-treated NMIBC recurrence.
Total patients BCG
& treated patients
*No.
unfavorable
genotypes Yes (no.) No (no.) HR
{ (95% CI) P
#No. unfavorable
genotypes Yes (no.) No (no.)
HR
{ (95%
CI) P
0–1 99 113 Ref. 0–1 52 48 Ref.
2 48 41 1.21 (0.85–1.71) 0.29 2 19 26 1.46 (0.90–
2.38)
0.13
3–6 64 34 2.21 (1.60–3.05) ,0.01 3–6 11 36 3.52 (2.23–
5.55)
,0.01
P for trend ,0.0001 P for trend ,0.0001
*Unfavorable genotypes in overall patients: NEIL2 rs4639(vv); NEIL2 rs804276(vv); NEIL2 rs804256(vv); NEIL2 rs1874546(vv); NEIL2 rs804267(vv); TDG rs4135064(ww+wv).
#Unfavorable genotypes in BCG treated patients: NEIL2 rs804256(vv); NEIL2 rs804276(vv); NEIL2 rs4639(vv); SOD1 rs2173962(wv+vv); NEIL2 rs804267(ww+wv); NEIL2
rs8191604(ww+wv).
&Patients treated with iBCG or iBCG plus mBCG.
{HR: hazard ratio, CI: confidential interval. Adjusted by age, sex, smoking status, tumor stage, and tumor grade.
doi:10.1371/journal.pone.0038533.t002
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(P,0.01).
Analyses of Disease Recurrence Stratified by Treatment
Twenty five SNPs were significantly associated with recurrence
risk in overall patients, and after adjusting for multiple compar-
isons, 6 remained significant, with a q-value #0.1 (Table S2). In
the TUR patients, 34 SNPs were significantly associated with
recurrence risk (P,0.05) but after adjusting for multiple compar-
isons none remained significant (Table S3). In the BCG-treated
patients, 28 SNPs were significantly associated with recurrence,
and after adjusting for multiple comparisons, 6 remained
significant, with a q-value #0.1 (Table 1; Table S4).
To internally validate these results, we performed random
bootstrap sampling of the significant SNPs for 100 iterations and
listed the number of times that the P value was ,0.05. In BCG-
treated patients, four of the five top SNPs in NEIL2 had highly
consistent results, with bootstrap P values ,0.05 for greater than
90% of samplings (Table 1).
Cumulative Effects of Multiple SNPs on Recurrence in
NMIBC Patients
We summed the number of unfavorable genotypes for each
individual and categorized the patients by tertile distribution of
their recurrence risk, which showed dose-dependent trend among
three groups (P trend ,0.0001). In total patients, compared with
the low-risk group, the median-risk and high-risk groups had a 1.2-
Figure 2. NEIL2:rs4639 alleles are targeted by miRNAs. rs4639 (A/G) SNP position and presumed pattern of miRNA binding with hsa-
miR-421 and hsa-miR-1200 (Targetscan). Result of dual luciferase reporter assay showing the effects of rs4639 variant, hsa-mir-421 (2421), and
hsa-mir-1200 (21200) on reporter expression. All values were normalized to the Renilla luciferase activities and expressed as percentages of the
luciferase activity for cells transfected with wild-type reporter construct and negative control RNA (Ctrl). Values are averages of five replicates with
error bars for standard deviation. **, P,0.01 by Wilcoxon Ranksum test. Assay was repeated three times with similar results.
doi:10.1371/journal.pone.0038533.g002
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CI, 1.60–3.05) higher risk of recurrence, respectively (P,0.01;
Table 2). Among BCG (iBCG alone or iBCG plus mBCG)
treated patients, compared with the low-risk group, the median-
risk and high-risk groups had a 1.46-fold (HR, 1.46, 95% CI, 0.9–
2.38) and a 3.5-fold (HR, 3.52, 95% CI, 2.23–5.55) higher
recurrence risk, respectively (P,0.01; Table 2). Kaplan-Meier
estimates of the total and BCG-treatment groups indicated
differences in median recurrence-free survival times (MST) (log
rank test, P=0.0001; Figure 1 A and B).
Effects of SNPs on Disease Progression
In the NMIBC patients, 23 SNPs were significantly associated
with progression (P,0.05, Table 3). After adjusting for multiple
comparisons, one SNP, UNG:rs3890995, remained significant
(Q=0.08) and had a highly consistent result, with bootstrap P
value ,0.05 for 90% times of samplings (Table 3). The median
progression-free survival times were longer than the follow-up time
of 132.6 months for all genotypes (Figure 1 C). However,
patients who carried the homozygous variant alleles had a 1.92-
fold (HR 1.92, 95% CI, 1.33–2.77) higher progression risk
(Table 3) and had decreased progression-free survival (log-rank
test, P=0.04; Figure 1 C). Due to the limited number of
progression cases, we did not perform similar analysis in BCG-
treated patients.
Effects of hsa-mir-421 and hsa-mir-1200 on NEIL2
Expression
Since one of the most significant SNPs, NEIL2:rs4639, is located
in the gene’s 39UTR, we scanned the NEIL2 39 UTR region for
potential miRNA binding sites Targetscan (www.targetscan.org).
Results showed that rs4639 allele is located close to a potentially
weak binding site for the miRNAs hsa-miR-421 and hsa-miR-
1200 (Figure 2). We cloned 39UTR of NEIL2 and analyzed the
effects of this SNP on the miRNA-mediated expression regulation.
The two miRNAs had similar inhibitory effects on both wildtype
and variant rs4639 expression (Figure 2), suggesting
NEIL2:rs4639 might not affect targeting by these miRNAs.
Discussion
We evaluated the association of a panel of 276 SNPs in 38
oxidative-stress genes with the recurrence of NMIBC in patients
treated with or without BCG. We identified 25 SNPs that were
significantly associated with cancer recurrence in all (TUR- and
BCG-treated) patients, 34 significant SNPs in TUR only patients,
Table 3. Oxidative stress gene SNPs and disease progression in NMIBC patients receiving BCG treatment.
Progression Yes/No
No. of
bootstrap
samples
{
SNP Gene Best Model
# ww wv+vv vv HR (95% CI)
{ PP ,0.05
rs3890995* UNG ADD 42/242 27/77 6/8 1.92(1.33–2.77) 5610
24 90
rs1874546 NEIL2 DOM 34/201 35/100 5/24 1.89(1.18–3.03) 0.01 –
rs12674710 NAT2 REC 48/230 22/90 5/7 3.47(1.37–8.81) 0.01 –
rs11773597 CYP3A4 DOM 59/277 16/47 0/3 2.18(1.21–3.93) 0.01 –
rs1805410 PARP1 DOM 48/248 24/72 3/7 1.92(1.17–3.12) 0.01 –
rs1799930 NAT2 DOM 48/155 22/137 5/34 0.53(0.33–0.86) 0.01 –
rs1013358 MPG ADD 49/254 22/68 4/5 1.67(1.13–2.48) 0.01 –
rs5751222 CYP2D6 REC 47/202 21/106 7/17 2.74(1.20–6.24) 0.02 –
rs9332197 CYP2C9 DOM 63/297 12/30 0/0 2.16(1.14–4.09) 0.02 –
rs3136717 IKBKB DOM 49/259 26/64 0/0 1.80(1.10–2.92) 0.02 –
rs915908 CYP2E1 DOM 61/225 14/95 0/7 0.50(0.28–0.89) 0.02 –
rs1050112 PARP4 REC 25/136 36/151 14/40 2.00(1.10–3.65) 0.02 –
rs2475377 CYP2C9 DOM 65/305 10/22 0/0 2.24(1.12–4.49) 0.02 –
rs976072 POLG REC 33/144 38/131 4/52 0.31(0.11–0.86) 0.02 –
rs1062492 NUDT1 DOM 43/217 31/95 1/15 1.71(1.07–2.74) 0.02 –
rs1858923 ABCB1 DOM 20/120 33/143 22/64 1.79(1.07–2.99) 0.03 –
rs1961456 NAT2 ADD 33/175 34/131 8/21 1.49(1.04–2.15) 0.03 –
rs4796030 LIG3 REC 24/96 42/158 9/73 0.46(0.23–0.94) 0.03 –
rs4680 COMT DOM 52/188 19/119 4/20 0.60(0.36–0.98) 0.04 –
rs4633 COMT DOM 24/72 34/180 17/72 0.60(0.37–0.98) 0.04 –
rs625978 GSTP1 DOM 26/73 32/162 17/92 0.61(0.37–0.99) 0.04 –
rs1866074 TDG REC 16/81 51/174 8/72 0.47(0.22–0.98) 0.04 –
rs1045642 ABCB1 ADD 24/91 36/153 15/83 0.73(0.53–1.00) 0.05 –
*SNPs that remained significant after controlling for multiple comparisons by q-value. (FDR,10%).
#Best model: the model with smallest P value; ADD: additive model, DOM: dominant model, RES: recessive model.
{HR: hazard ratio, CI: confidential interval. Adjusted by age, sex, smoking status, tumor stage, tumor grade, and treatment.
{SNPs not significant by q-value were not tested in bootstrapping method.
doi:10.1371/journal.pone.0038533.t003
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found significant gene-dosage effects from the cumulative analysis,
and identified one SNP associated with NMIBC progression.
The most significant SNP associated with recurrence in the
BCG-treated group was NEIL2:rs804256, which is located in the
intron region. Compared with the wild-type genotypes, the
recurrence risk for the homozygous variant CC genotype was
increased more than four-fold. However, this SNP was not
significant in TUR only subgroup, suggesting a potential in-
teraction of rs804256 with BCG treatment. Five out of six of the
most significant SNPs are located in NEIL2, which highlights the
importance of this gene in the recurrence risk. NEIL2 belongs to
a class of DNA glycosylases homologous to bacterial Fpg/Nei
family, which is essential for removing cytosine-derived lesions,
particularly 5-hydroxyuracil and 5-hydroxycytosine [22]. It has
been reported that two 59-UTR polymorphisms decrease NEIL2
expression and increase mutagen-induced genetic DNA damage
[23]. Downregulation of NEIL2 expression may lead to increased
oxidative stress and genomic instability in rapidly proliferating
tissues [24]. NEIL2 may also play important roles in repairing
DNA damage induced by carcinogenic metals [25]. One of the
most significant SNPs associated with recurrence, rs4639, is
located in 39-UTR of NEIL2. Luciferase reporter assay results
showed that hsa-mir-421 and hsa-mir-1200 miRNAs had similar
inhibitory effects on both wildtype and variant rs4639 expression.
Since either miRNAs showed similar inhibitory effects on both
wildtype and variant genotypes, it is possible that rs4639 may not
be the causative variant but functions as a tagging SNP for other
polymorphisms that may contribute to bladder cancer recurrence
by altering NEIL2 expression or function. Alternatively, the variant
allele of this SNP may affect targeting by other miRNAs. Future
fine mapping of the regions surrounding the most significant
tagSNPs are needed to identify the causal genetic variations and
their molecular mechanisms.
We also identified a significant gene-dosage effect for the six
tagging SNPs that showed significant main effects. Patients with
the largest number of unfavorable genotypes had the highest risk
of NMIBC recurrence, suggesting that additional risk genotypes
within this key pathway were detrimental. This highlights the
importance of assessing multiple SNPs within a shared pathway for
clinical outcome assessment.
One polymorphism, UNG: rs3890995, was significantly associ-
ated with NMIBC progression. Rs3890995 is located 1.87 kb
upstream of UNG 59 UTR. One important function of UNG is to
recognize and remove uracil from DNA by cleaving the N-
glycosylic bond and initiating the base-excision repair pathway.
DNA uracil comes from cytosine deamination or misincorporation
of dUMP residues [26]. It is possible that the variant allele of SNP
rs3890995 may affect gene transcription thus altering protein level.
Alternatively, it may be linked to other causal variants in UNG.
In summary, we showed that genetic polymorphisms of the
oxidative stress pathway genes may modulate the risk of NMIBC
recurrence and progression in BCG treated patients. Further, we
have conducted a relatively comprehensive query of the oxidative
stress pathway polymorphisms with detailed clinical information
and analyses, which provided substantial evidence for the in-
volvement of this pathway in the clinical outcomes of bladder
cancer patients, particularly with BCG treatment. There are some
limitations in this study. For example, only Caucasians were
included. It would be interesting to exam these SNPs in minority
populations. Additionally, sample size is not particularly large,
although power calculation showed that our analysis had sufficient
power (.80%) to detect the main effects analyzed. Although our
data are largely internally validated, future replication studies in
independent populations are needed to validate some of the results
and to translate the findings to clinical trials.
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